Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Mineralys Therapeutics Inc (MLYS)

Mineralys Therapeutics Inc (MLYS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,289,520
  • Shares Outstanding, K 79,140
  • Annual Sales, $ 0 K
  • Annual Income, $ -177,810 K
  • EBIT $ -184 M
  • EBITDA $ -184 M
  • 60-Month Beta 0.52
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.21

Options Overview Details

View History
  • Implied Volatility 128.86% (-7.58%)
  • Historical Volatility 60.42%
  • IV Percentile 94%
  • IV Rank 21.23%
  • IV High 403.07% on 02/28/25
  • IV Low 54.96% on 09/24/25
  • Expected Move (DTE 24) 7.03 (23.71%)
  • Put/Call Vol Ratio 1.20
  • Today's Volume 108
  • Volume Avg (30-Day) 5,078
  • Put/Call OI Ratio 1.60
  • Today's Open Interest 103,400
  • Open Int (30-Day) 95,328
  • Expected Range 22.62 to 36.68

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.57
  • Number of Estimates 4
  • High Estimate -0.50
  • Low Estimate -0.63
  • Prior Year -0.98
  • Growth Rate Est. (year over year) +41.84%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.85 +11.58%
on 02/19/26
33.63 -10.91%
on 01/27/26
-2.82 (-8.60%)
since 01/23/26
3-Month
26.85 +11.58%
on 02/19/26
44.13 -32.11%
on 11/26/25
-12.64 (-29.67%)
since 11/24/25
52-Week
8.24 +263.55%
on 02/25/25
47.65 -37.12%
on 11/12/25
+20.71 (+223.89%)
since 02/24/25

Most Recent Stories

More News
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

RADNOR, Pa., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related...

MLYS : 29.96 (+3.56%)
Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026

RADNOR, Pa., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related...

MLYS : 29.96 (+3.56%)
Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup

– Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful...

MLYS : 29.96 (+3.56%)
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

RADNOR, Pa., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related...

MLYS : 29.96 (+3.56%)
Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

– Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 – – Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 – – Conference...

MLYS : 29.96 (+3.56%)
Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025

– Late-breaking presentation of Explore-CKD trial at ASN Kidney Week – – Pivotal Phase 3 Launch-HTN trial featured in the “Best of JAMA and NEJM” session - RADNOR, Pa., Nov. 07, 2025...

MLYS : 29.96 (+3.56%)
Mineralys Therapeutics to Participate in Upcoming Investor Conferences

RADNOR, Pa., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related...

MLYS : 29.96 (+3.56%)
Mineralys Therapeutics to Announce Third Quarter 2025 Financial Results and Host Conference Call on Monday, November 10, 2025

RADNOR, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related...

MLYS : 29.96 (+3.56%)
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025

~ Late-breaking Phase 2 trial data evaluating the safety and efficacy of 25 mg of lorundrostat in participants with hypertension and comorbid CKD to be presented~ ~ Phase 3 data of the Launch-HTN...

MLYS : 29.96 (+3.56%)
Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension

~ Topline results from the EXPLORE-OSA trial are anticipated in 1Q 2026 ~ RADNOR, Pa., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical...

MLYS : 29.96 (+3.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Mineralys Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Mineralys Therapeutics Inc. is based in RADNOR, Pa.

See More

Key Turning Points

3rd Resistance Point 31.40
2nd Resistance Point 30.46
1st Resistance Point 29.70
Last Price 29.96
1st Support Level 28.00
2nd Support Level 27.06
3rd Support Level 26.30

See More

52-Week High 47.65
Fibonacci 61.8% 32.60
Last Price 29.96
Fibonacci 50% 27.95
Fibonacci 38.2% 23.30
52-Week Low 8.24

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar